Lexaria Signs Manufacturing and License Agreements with BevNology

June 21, 2022 9:00 AM

Expands DehydraTECH™ B2B manufacturing capabilities to support Lexaria's growing corporate customer baseLexaria to also receive royalty revenue from DehydraTECH product sales through BevNology's commercial license rightsKELOWNA, BC / ACCESSWIRE / June 21, 2022 / Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms is pleased to announce the signing of two...

Read more

Enzolytics Announces the Discovery of Conserved Target Sites on the Monkeypox Virus

June 21, 2022 6:00 AM

COLLEGE STATION, TX / ACCESSWIRE / June 21, 2022 / Enzolytics, Inc. (OTC PINK:ENZC) (ENZC" or the "Company") today announced it has identified conserved, immutable sites (epitopes) on the Monkeypox virus. These discoveries are a part of Enzolytics' continuing efforts to address future healthcare needs in pandemics using its Comprehensive Artificial Intelligence (AI) protocol for producing Monoclonal Antibodies, including implementing AI analysis...

Read more

Year-end Report 2021/2022 - Preparations for the Upcoming US Launch

June 16, 2022 2:20 AM

UPPSALA, SWEDEN / ACCESSWIRE / June 16, 2022 / Biovica International (STO:BIOVIC-B)(STO:BIOVIC.B)(FRA:9II)SEK thousandsQ4 21/22Q4 20/21May-April 21/22May-April 20/21Net sales1,0823182,0452,077Operating profit (loss)-19,132-12,169-60,101-40,181Profit (loss) for the period-19,056-11,992-60,003-39,482Earnings per share, after dilution-0.67-0.42-2.11-1.39Significant events during the fourth quarterUpdated timetable for supplementation of the FDA...

Read more

Notice to Extraordinary General Meeting in BioInvent International AB

June 16, 2022 2:00 AM

LUND, SE / ACCESSWIRE / June 16, 2022 / BioInvent International (STO:BINV)The shareholders of BioInvent International AB (publ), Reg. No 556537-7263, are hereby invited to attend the Extraordinary General Meeting (the "EGM") to be held on Tuesday 12 July 2022. The EGM will be held only through advance voting (postal voting) in accordance with temporary legislation.A. NOTICE OF ATTENDANCEShareholders who wish to attend the EGM must:(i)...

Read more

Natalie Berner of Redmile and Nanna Lüneborg of Forbion proposed as New Board Members of BioInvent

June 16, 2022 2:00 AM

LUND, SWEDEN / ACCESSWIRE / June 16, 2022 / BioInvent International AB ("BioInvent") (NASDAQ Stockholm:BINV), a biotech company focused on the discovery and development of novel and first-in-class immune-modulatory antibodies for cancer immunotherapy, today announces on behalf of the nomination committee, the proposal to elect Natalie Berner and Nanna Lüneborg as new Board members, at the Extraordinary General Meeting...

Read more

Lumira Ventures Expands Presence in Western Canada Continuing Commitments to Support and Enhance the Growth of Companies in the Region

June 15, 2022 7:00 AM

TORONTO, ON / ACCESSWIRE / June 14, 2022 / Lumira Ventures, a leading global healthcare venture capital firm, announced today that Partner, Lu Han Ph.D. has relocated to the firm's office in Vancouver, British Colombia."It has been inspiring to witness the amazing growth of the life sciences ecosystem in B.C over the last several years," commented Lu Han. "I'm looking forward to building our presence in British Columbia and throughout western...

Read more

Dermata Announces Final Patient Enrolled in a Phase 2 Trial of DMT310 for the Once-Weekly Treatment of Moderate-to-Severe Rosacea

June 13, 2022 9:00 AM

- Topline results expected in the second half of 2022 -- Rosacea affects about 16 million patients in the U.S. -SAN DIEGO, CA / ACCESSWIRE / June 13, 2022 / Dermata Therapeutics, Inc. ("Dermata," or the "Company") (NASDAQ:DRMA), a clinical-stage biotechnology company focusing on the treatment of medical and aesthetic skin conditions, today announced it has completed enrollment of its Phase 2 trial of DMT310 for the once-weekly treatment of...

Read more

DiviTum®TKa Predicts Clinical Outcome of Patients in BioItaLEE Study

June 13, 2022 4:20 AM

UPPSALA, SE / ACCESSWIRE / June 13, 2022 / Biovica International (STO:BIOVIC-B) (STO:BIOVIC.B) (FRA:9II)Biovica today announced that the company's blood test DiviTum®TKa was highlighted in an oral presentation on June 6th at the ASCO Annual Meeting from the BioItaLEE trial. The study results suggest that TKa can predict patients' response to a CDK4/6 treatment.The BioItaLEE trial is a Novartis sponsored Italian multicenter study of 287...

Read more

BioInvent Appoints Sylvie Ryckebusch as Chief Business Officer

June 9, 2022 2:55 AM

Over 20 years' experience as pharmaceutical business development executiveWill join BioInvent's executive management teamLUND, SE / ACCESSWIRE / June 09, 2022 / BioInvent International AB ("BioInvent") (Nasdaq Stockholm: BINV), a biotech company focused on the discovery and development of novel and first-in-class immuno-modulatory antibodies for cancer immunotherapy, today announces the appointment of Sylvie Ryckebusch as Chief...

Read more

Aqualung Therapeutics Appoints Two New Board Directors; Will Attend June 22 Bio Meeting in San Diego

June 8, 2022 5:45 PM

TUCSON, AZ / ACCESSWIRE / June 8, 2022 / Aqualung Therapeutics, an early stage immunotherapeutics biotech company developing an anti-inflammatory therapeutic platform for serious unchecked inflammatory disorders, unanimously appointed two highly accomplished entrepreneurs and scientists to the recently formed Aqualung Therapeutics Board of Directors. Industry experts Donald Payan MD and Robert Schleimer PhD will officially begin their Board...

Read more

Lexaria Grants License to AnodGen Bioceuticals

June 8, 2022 9:00 AM

DehydraTECH Pharmaceutical License Issued for the European, Australian and New Zealand marketsLexaria to receive royalty revenue from DehydraTECH product salesKELOWNA, BC / ACCESSWIRE / June 8, 2022 / Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms is pleased to announce the awarding of a five-year, non-exclusive DehydraTECH license (the "License") from its...

Read more

Oncology Pharma Announces: Initial Feasibility Study of the Nanoemulsion Drug Delivery System is Complete and Results Have Met the Threshold for Moving Forward To the Next Steps of Development

June 8, 2022 7:30 AM

SAN FRANCISCO, CA / ACCESSWIRE / June 8, 2022 / Oncology Pharma Inc. (OTC PINK:ONPH) - Oncology Pharma, Inc. ("The Company") is pleased that the initial feasibility stage is complete and results have met the threshold to move forward.The formulation under development consisted of the active pharmaceutical ingredient (dactinomycin) encapsulated in a saturated lipid and combined with various emulsifiers, surfactants, and stabilizers. The specific...

Read more

Hemogenyx Pharmaceuticals PLC Announces Posting of Annual Report & Notice of AGM

June 7, 2022 11:00 AM

LONDON, UK / ACCESSWIRE / June 7, 2022 / Hemogenyx Pharmaceuticals plc (LSE:HEMO), the biopharmaceutical group, confirms that the Annual Report and Accounts for the year ended 31 December 2021, the Notice of the Annual General Meeting ("AGM") and a Form of Proxy were posted to shareholders today and are available on the Company's website at https://hemogenyx.com/investors/annual-and-half-year-reports, and the 2021 Equity Incentive Plan with...

Read more

Black Bird Biotech Announces Second Successful MiteXstream Honey Bee Test Results: Not Toxic to Honey Bees When Ingested

June 7, 2022 8:55 AM

FLOWER MOUND, TX / ACCESSWIRE / June 7, 2022 / Black Bird Biotech, Inc. (OTC PINK:BBBT), manufacturer of plant-based MiteXstreamTM biopesticide, today announced that, in additional independent lab testing, MiteXstreamTM was proven to be "NOT TOXIC" to honey bees when they ingest the biopesticide. The Honey Bee Report on Oral Toxicity can be found here.The company had previously announced that MiteXstreamTM tested as "NOT TOXIC" to honey bees...

Read more

Nascent Biotech Completes Third Cohort in Phase 1 Human Trial for Primary and Metastatic Brain Cancer

June 7, 2022 8:00 AM

VERO BEACH, FL / ACCESSWIRE / June 7, 2022 / Nascent Biotech, Inc. (OTCQB:NBIO) ("Nascent Biotech", "Nascent", or the "Company"), a clinical-stage biotechnology Company pioneering the development of monoclonal antibodies targeting treatment of various cancers and viral infections, is pleased to announce the completion of the Third cohort in dosing patients for its Phase I trial for Brain Cancer. After reviewing the data gathered from the first...

Read more

Lumira Ventures Team Expansion: David Novak Announced as New Venture Partner

June 7, 2022 7:00 AM

TORONTO, ON / ACCESSWIRE / June 7, 2022 / Lumira Ventures, a leading global healthcare venture capital firm, announced today the addition of David Novak to its investment team as a Venture Partner.Mr. Novak brings to Lumira Ventures extensive capital markets, industry, and clinical research experience having most recently served as a Managing Director at Raymond James, a large global investment dealer, where he covered North American...

Read more

Lexaria Files Pre-IND Meeting Request Letter with U.S. FDA

June 6, 2022 9:15 AM

KELOWNA, BC / ACCESSWIRE / June 6, 2022 / Lexaria Bioscience Corp. (Nasdaq:LEXX)(Nasdaq:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms is pleased to announce it has successfully filed a pre-Investigational New Drug ("IND") meeting request letter with the U.S. Food and Drug Administration ("FDA"). The FDA has already responded to and confirmed Lexaria's filing. A target date of July 30, 2022, has been provided...

Read more

Lexaria Grants Exclusive License to Premier Wellness Science Co., Ltd. for Strategic and Long-Term Partnership in the Japanese Market

June 3, 2022 2:00 AM

Minimum payments due to Lexaria of US$4,527,500 over the first five years to retain exclusivityLexaria to receive royalty revenue from DehydraTECH product salesKELOWNA, BC / ACCESSWIRE / June 2, 2022 / Lexaria Bioscience Corp. (NASDAQ:LEXX) (NASDAQ:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms is pleased to announce a significant exclusive* commercial licensing agreement (the "Agreement") in Japan with...

Read more

Lexaria Grants License to Valcon Medical for the European Market

June 2, 2022 9:05 AM

Contract Manufacturing Organization first in Europe to License DehydraTECHLexaria will receive milestone fees and royalty payments from product salesKELOWNA, BC / ACCESSWIRE / June 2, 2022 / Lexaria Bioscience Corp. (Nasdaq:LEXX) (Nasdaq:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms is pleased to announce the awarding of a European and United Kingdom ("UK") DehydraTECH license for medical cannabis...

Read more

Xenetic Biosciences, Inc. to Participate in the Virtual Investor Innovation in Oncology Event

June 2, 2022 8:35 AM

Live Video Webcast With Moderated Roundtable With Members of the Xenetic Leadership Team and Surgical Oncology Key Opinion Leader, Allan Tsung, MD on Thursday, June 9th at 11:00 AM ETFRAMINGHAM, MA / ACCESSWIRE / June 2, 2022 / Xenetic Biosciences, Inc. (NASDAQ:XBIO) ("Xenetic" or the "Company"), a biopharmaceutical company focused on advancing innovative immune-oncology technologies for the treatment of hard to treat cancers, today announced...

Read more